Journal of Pharmacovigilance

Abstract

A Review on Adverse Drug Events to Create Awareness

Pallavi Jaiswal

Adverse Drug Events (ADE) reporting is the foundation of any Pharmacovigilance system. There is always a risk in the proactive management of newly marketed drugs. Most drugs are used in a larger population after their commercialization than in clinical trials. It is important to detect the full safety profile of the drug before its marketing and throughout its marketing period. The post marketing pharmacovigilance provides the assurance of rational and safe use of medications. The medical practitioners and the pharmacovigilance body under the guidance of World Health Organization are responsible for the risk management system of a drug in different countries. The level of education and training on ADE reporting has improved the Pharmacovigilance of many drugs. Education and training is the most recognized means of improving ADE reporting.